Snezana is a myeloma patient the president of the Serbian Association of Myeloma Patients (Udruženje obolelih od multiplog mijeloma Srbije). She spent years working as a business consultant covering finance, regulatory frameworks, international trade and distribution and also served as finance director with extensive experience at board level. Snezana’s mission is sharing knowledge, experiences, advocacy strategies, and developing collaboration between different EU regions to improve the capacities of CEE country myeloma associations.
US Food and Drug Administration (FDA) issues draft guidance on minimal residual disease
The US Food and Drug Administration (FDA) has issued draft guidance to the pharmaceutical industry on using minimal residual disease (MRD) and complete response (CR) in myeloma clinical trials as…